<scp>PRAME</scp> expression in cellular neurothekeoma: A study of 11 cases

Cesinaro, Anna Maria; Piana, Simonetta; Paganelli, Alessia; Pedroni, Gioia; Santandrea, Giacomo; Maiorana, Antonino

doi:10.1111/cup.14163

Cited by 11 publications

(9 citation statements)

References 23 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is consistent with the previously reported pattern of PRAME expression in squamous cell carcinoma [19]. PRAME is not specific to a cell lineage and has been described in tumors of non-melanocytic origin including colon adenocarcinoma, cellular neurothekeoma, and some lymphomas [20][21][22]. Not surprisingly, expression of PRAME was identified in several of our non-melanocytic lesions.…”

Section: Discussionsupporting

confidence: 93%

PRAME Expression in Mimickers of Melanoma in Situ: Paget's Disease, Extramammary Paget's Disease, and Pagetoid Squamous Cell Carcinoma In Situ

Cary¹,

Michael²,

Sage³

et al. 2022

Int J Pathol Clin Res

View full text Add to dashboard Cite

Background: Antibodies towards Preferentially Expressed Antigen in Melanoma (PRAME) have shown promise to discriminate between melanoma in situ (MIS) and benign melanocytic lesions. Paget's disease, extramammary Paget's disease, and squamous cell carcinoma in situ may mimic the morphologic features of MIS, and PRAME expression in these lesions has not yet been described.Methods: Three cases of Paget's disease, 11 of extramammary Paget's disease, 15 squamous cell carcinoma in situ cases, and two collision tumors (extramammary Paget's disease and squamous cell carcinoma in situ) were entered into this study.Results: One of 15 cases of squamous cell carcinoma in situ showed focal, weak PRAME positivity. One case of Paget's disease of the breast showed weak, diffuse positivity as did one collision tumor. Five of 11 cases of extramammary Paget's disease displayed positive nuclear PRAME staining with three showing various degrees of cytoplasmic positivity (negative nuclear staining). Conclusions:Although PRAME has shown utility in the diagnosis of MIS, it is not lineage specific. PRAME shows variable expression in mimickers of MIS, and other immunostains should be used to confirm the diagnosis of pagetoid lesions. Positive PRAME staining does seem to suggest a non-squamous tumor lineage, however.

show abstract

Section: Discussionsupporting

confidence: 93%

PRAME Expression in Mimickers of Melanoma in Situ: Paget's Disease, Extramammary Paget's Disease, and Pagetoid Squamous Cell Carcinoma In Situ

Cary¹,

Michael²,

Sage³

et al. 2022

Int J Pathol Clin Res

View full text Add to dashboard Cite

show abstract

“…In addition, 1 study 8 shows a very low expression of PRAME inferior to 1% of cells in 5 of the 8 cases of lentigo malignant tested. On the other hand, some studies 5,7–10 have underlined that a minority of benign melanocytic nevi (between less than 10% to 20%) show a focal expression of PRAME with a great variability in the distribution of the positive cells from case to case between 1 to lesser than 75% of cells. In addition, the diffuse…”

Section: Discussionmentioning

confidence: 99%

Preferentially Expressed Nuclear Antigen in Melanoma Expression in Melanocytic Activation (Melanotic Macule) of the Nail Unit. A Potential Diagnostic Pitfall? A Study of 3 Cases

Perrin¹

2022

The American Journal of Dermatopathology

View full text Add to dashboard Cite

Recent studies have argued that melanocyte preferentially expressed nuclear antigen in melanoma (PRAME) is a sensitive and specific immunohistochemical marker of melanoma, including acral melanoma. In addition, loss of p16 expression has recently been suggested to have diagnostic utility in acral melanocytic tumors. The purpose of this study was to report PRAME expression in 3 cases of melanocytic activation (MAN). There were 2 men and 1 woman ranging in age at diagnosis from 46 years to 78 years (mean 61, 6 years). All cases involved a single digit. One lesion was in the fingernail (fifth finger), whereas the remaining 2 lesions were in the toenails (hallux). All the patient presented with a longitudinal melanonychia. The width of the lesions varied from 3 mm (2 cases) to 4 mm (1 case). The duration of the lesions before diagnosis varied from 12 to 24 months. Distinction of MAN from melanoma in situ is not always easy. Some morphological misleading features are illustrated in this study: (1) the suprabasal location of matrix melanocytes with long and thick dendrites within the 2-4 germinative cell layers; (2) the microconfluence of 2 melanocytes and rare melanocytes with a relatively large nucleus, however in a general context of melanocyte scarcity; and (3) the occasional nonspecific nuclear microphtalmia-associated transcription factor (MITF) staining of keratogeneous cells. Such staining could suggest a pagetoid spread of melanocytes in the keratogenous zone. PRAME antibody revealed a strong and diffuse staining in all cases. In addition, all cases were p16 negative. In this study, the melanocyte count inferior to 9 melanocytes/mm and the lack of nuclear atypia or confluence of melanocytes permitted a confident diagnosis of MAN. Limitations of our study lie largely in the small number of cases. Despite this, the expression of PRAME in some MAN seems to hamper its diagnostic value in differentiating benign from malignant lesion.

show abstract

“…On the other hand, other studies have reported that immunostaining for PRAME can also be used in other neoplastic settings, including soft tissue sarcomas [ 8 ], non-small cell lung cancer [ 9 ], breast carcinoma [ 10 ], renal cell carcinoma [ 11 ], ovarian carcinoma [ 12 ], leukemia [ 13 ] and synovial sarcoma [ 14 ]. In this background, the importance and use of PRAME in non-melanoma skin cancer skin lesions have not yet been reported in the literature, with only a few works that have tried to shed light on the topic [ 15 , 16 , 17 , 18 ].…”

Section: Introductionmentioning

confidence: 99%

PRAME Immuno-Expression in Cutaneous Sebaceous Carcinoma: A Single Institutional Experience

Cazzato

Colagrande

Ingravallo

et al. 2022

JCM

View full text Add to dashboard Cite

Background: In recent years, great research interest has been directed to the diagnostic, therapeutic and marker role of Preferentially expressed Antigen in Melanoma (PRAME) in the setting of various human neoplasms. Although it has been extensively studied mainly in the differential diagnosis setting of melanocytic pigmented lesions, still very few papers have analyzed the usefulness or otherwise of PRAME in the context of other non-melanoma skin cancers (NMSC). (2) Methods: In this paper, we report the data of our experience of 21 cases of sebaceous carcinoma (SC) classified in the three WHO grade and collected in the period between January 2005 and 31 October 2022, on which immunostaining for PRAME was performed; Non-parametric Mann–Whitney test for non-normally distributed values was performed. A comparison was made of the means between the three study groups (grade I, II and III). A value of p ≤ 0.05 was set as statistically significant (3) Results: Only seven cases (33.3%) were positive with an immunoscore of 2+/3+ for intensity and 1+/2+ for percentage cells positivity, while 14 cases (66.6%) were totally or nearly totally negative for PRAME with a few of sebaceous-like cells positive with an immunoscore of 1+. Eight cases of SC grade I were immunostaining for PRAME, a level of the cytoplasm of foci of sebaceous differentiation with a significant statical value (p < 0.0001) with respect to ten cases of SC grade II; furthermore, the eight cases of grade I were positive for PRAME in the same areas respect the 3 cases of SC grade III (p = 0.0303). There were no statistical significance between the 10 cases of grade II and 3 cases of grade III (p = 0.2028); (4) Conclusions: PRAME not seems to add particular information in the case of histopathological diagnostics of SC where other markers, including adipophylline, can be quite indicative. It seems, on the other hand, that PRAME can be useful in the subclassification setting of sebaceous carcinoma in grades I–II–III according to the directives of the latest WHO 2018, highlighting the foci of mature sebaceous differentiation most present in grades 1–2 and almost completely absent in grade 3 of the SC.

show abstract

PRAME expression in cellular neurothekeoma: A study of 11 cases

Cited by 11 publications

References 23 publications

PRAME Expression in Mimickers of Melanoma in Situ: Paget's Disease, Extramammary Paget's Disease, and Pagetoid Squamous Cell Carcinoma In Situ

PRAME Expression in Mimickers of Melanoma in Situ: Paget's Disease, Extramammary Paget's Disease, and Pagetoid Squamous Cell Carcinoma In Situ

Preferentially Expressed Nuclear Antigen in Melanoma Expression in Melanocytic Activation (Melanotic Macule) of the Nail Unit. A Potential Diagnostic Pitfall? A Study of 3 Cases

PRAME Immuno-Expression in Cutaneous Sebaceous Carcinoma: A Single Institutional Experience

Contact Info

Product

Resources

About